Dr. Brahmer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
401 N. Broadway
Baltimore, MD 21231Phone+1 410-955-8964Fax+1 410-614-9334- Is this information wrong?
Summary
- Dr. Julie Brahmer is an oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. She received her medical degree from University of Nebraska College of Medicine and has been in practice 24 years. She specializes in thoracic oncology and is experienced in gastrointestinal oncology, and general medical oncology.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1997 - 2000
University of Utah HealthResidency, Internal Medicine, 1993 - 1997
University of Nebraska College of MedicineClass of 1993
Certifications & Licensure
FL State Medical License 2021 - Present
DC State Medical License 2022 - 2024
VA State Medical License 2023 - 2024
MD State Medical License 1997 - 2024
UT State Medical License 1994 - 1998- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- Fellow (FASCO) American Society of Clinical Oncologists, 2011
Clinical Trials
- Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2004 Sep 01
- Broccoli Sprout Extract in Preventing Lung Cancer in Smokers Start of enrollment: 2005 Jan 01
- Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2005 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- Unmet Needs, Quality of Life, and Financial Toxicity Among Survivors of Lung Cancer.Sarah Olson, Cyd Eaton, Laura Prichett, Matthew Guo, Mattea Miller, Michelle Turner, Melinda L Hsu, Mary C Boulanger, Julie Brahmer, Patrick M Forde, Kristen A Marrone...> ;JAMA Network Open. 2024 Apr 1
- Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.Mari Nakazawa, Guilherme Harada, Paola Ghanem, Adrian Bubie, Lesli A Kiedrowski, Joseph C Murray, Kristen A Marrone, Susan C Scott, Stefanie Houseknecht, Christina J F...> ;Cancer Research Communications. 2024 Mar 14
- 4 citationsElucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer.Murray, J., Sivapalan, L., Hummelink, K., Balan, A., White, J., Niknafs, N., Rhymee, L., Pereira, G., Rao, N., Weksler, B., Bahary, N., Phallen, J., Leal, A., Bartlett...> ;Clinical Cancer Research. 2024 Jan 17
- Join now to see all
Journal Articles
- Immune-Related (IR)-Pneumonitis During the COVID-19 Pandemic: Multidisciplinary Recommendations for Diagnosis and ManagementJoshua E Reuss, Karthik Suresh, David Feller-Kopman, Clare Rock, Julie R Brahmer, Journal For Immunotherapy of Cancer
Lectures
- Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.2019 ASCO Annual Meeting - 6/1/2019
- General Management of Immune-Related Toxicities Incorporating Guidelines Into Practice2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
- Emerging Strategies in Treatment of Non−Small-Cell Lung Cancer and Head & Neck Cancer 2012CancerNet, LLC, Atlanta, Georgia - 6/16/2012
Authored Content
- Evaluation of Health-Related Quality of Life and Symptoms in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Treated with Nivolumab or Docetaxel in CheckMate 057September 2018
Press Mentions
Initiative for Managing Adverse Events of Immunotherapy Leads to Clinical Practice Changes at MD AndersonApril 4th, 2023- Cancer Research Institute Virtual Immunotherapy Patient Summit Is Now Available Free, on-DemandDecember 8th, 2022
- Long-Term Clinical Benefit with Nivolumab plus Ipilimumab Extends Beyond Treatment Discontinuation in Patients with Metastatic NSCLC, Regardless of PD-L1 ExpressionOctober 18th, 2022
- Join now to see all
Committees
- Member, Update Committee of the ASCO NSCLC Expert Panel, American Society of Clinical Oncology 2015 - Present
Professional Memberships
- Fellow
Hospital Affiliations
Johns Hopkins HospitalBaltimore, Maryland
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/julie-brahmer
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
